Abbott Laboratories confirmed that its acquisition of Exact Sciences is set to close on March 23, 2026, a deal that will fundamentally reshape the cancer screening diagnostics market and reconfigure how R&D resources flow within the combined entity.
The transaction brings together Abbott’s global distribution infrastructure and medical device portfolio with Exact Sciences’ flagship Cologuard colorectal cancer screening test, which has built a substantial position in the US preventive care market.
For Abbott, the strategic logic is straightforward. Cancer screening is one of the fastest-growing segments in diagnostics, driven by an ageing population, improving detection technology, and growing insurance coverage for preventive tests.
Adding Exact Sciences’ molecular testing capabilities and its direct-to-consumer positioning gives Abbott a meaningful presence in a segment where it previously had limited exposure.
The market share implications are significant. Exact Sciences has spent years building physician relationships and consumer brand awareness around Cologuard, and under Abbott’s commercial umbrella, the reach of that product could expand considerably — both domestically and internationally, where colorectal screening adoption has lagged the US.
Abbott’s existing laboratory and clinical partnership networks provide the distribution pipes that Exact Sciences could never have built independently at the same pace.
From an R&D perspective, the combination raises interesting questions about how capital will be allocated. Exact Sciences has several next-generation blood-based cancer detection products in development, part of a broader industry race toward multi-cancer early detection — sometimes called MCED. Abbott’s acquisition may accelerate those timelines by injecting resources and clinical trial infrastructure that a standalone Exact Sciences would have struggled to access at the same scale.
The deal also reflects a broader consolidation trend in diagnostics. Post-pandemic, the sector has been rationalising as revenue from COVID-related testing normalised and companies looked for durable growth drivers. Cancer screening, digital pathology, and AI-assisted diagnostics have emerged as the primary battlegrounds — and scale matters enormously in all three.
